---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-015470"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:05:08.043709+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn reports preclinical AACR data for FHD-909, CBP/EP300 degraders; IND on track Q2 2024

## Summary
- FHD-909, a first-in-class BRM selective inhibitor, shows ~30-fold selectivity over BRG1 and dose-dependent tumor growth inhibition in BRG1 mutant xenografts.
- IND filing for FHD-909 in BRG1-mutant NSCLC on track for Q2 2024; developed with Lilly.
- Selective CBP degrader demonstrates tumor growth inhibition in solid tumors without thrombocytopenia or anemia.
- Selective EP300 degrader shows efficacy in prostate cancer and DLBCL models with no platelet effects.
- Conference call today at 5 pm ET to review pipeline updates.

## SEC filing metadata
- accession: 0001628280-24-015470
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024015470/0001628280-24-015470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024015470/fhtx-20240409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-015470
- JSON: https://secwatch.observer/filing/0001628280-24-015470.json
- Plain text: https://secwatch.observer/filing/0001628280-24-015470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.